Brind.

Financial Firms Update Ratings and Holdings for Vir Biotechnology

1 report, 1 independent Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Institutional investors have recently modified their holdings in Vir Biotechnology. Pictet Asset Management Holding SA cut its holdings by 2.5% during the third quarter, while Royal Bank of Canada grew its position in shares of Vir Biotechnology by 223.1% during the first quarter. Amundi also boosted its holdings by 52.8% in the first quarter.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

Analyst coverage from firms like Morgan Stanley and TD Cowen, combined with institutional investment activity, influences the market valuation of Vir Biotechnology. Currently, institutional investors and hedge funds own 65.32% of the company’s stock.

From themarketsdaily.com

Who's involved

  • VIR BiotechnologyBiotech company subject to rating and holding updates
  • Royal Bank of CanadaFinancial institution that increased its investment position in Vir Biotechnology
  • Morgan StanleyInvestment bank that issues and updates price targets and ratings for Vir Biotechnology
  • TD CowenInvestment bank that provides investment ratings and coverage for Vir Biotechnology

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • VIR BiotechnologySpeculative

    Vir Biotechnology might see changes in market price driven by analyst upgrades and institutional buying.

  • Royal Bank of CanadaSpeculative

    Royal Bank of Canada might adjust its portfolio allocation based on its investment thesis for Vir Biotechnology.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped